B.Riley Financial analyst Yuan Zhi initiated coverage with a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $16.00. The company's shares closed yesterday at $6.18.According to TipRanks, Zhi is an analyst with an average return of -12.0% and a 21.43% success rate. Zhi covers the Healthcare sector, focusing on stocks such as Azenta, IVERIC bio, and Actinium Pharmaceuticals.Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $28.67, representing a 363.92% upside. In a report released on August 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-has-a-new-rating-from-b-riley-financial?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Oct 2022 à Nov 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Nov 2021 à Nov 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals